H.C. Wainwright Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Maintains Target Price $11
Roth MKM Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Maintains Target Price $8
Niagen Bioscience (NAGE) Gets a Buy From Roth MKM
H.C. Wainwright Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Maintains Target Price $11
Niagen Bioscience Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Niagen Bioscience, Maintains $11 Price Target
H.C. Wainwright Maintains ChromaDex(CDXC.US) With Buy Rating, Maintains Target Price $11
ChromaDex Analyst Ratings
Chromadex's Strategic Rebranding and Promising Clinical Developments Justify Buy Rating
ChromaDex Is Maintained at Buy by HC Wainwright & Co.
ChromaDex Analyst Ratings
Ladenburg Thalmann Maintains Buy on ChromaDex, Raises Price Target to $8.1
Roth MKM Maintains ChromaDex(CDXC.US) With Buy Rating, Maintains Target Price $8
Chromadex (CDXC) Gets a Buy From Roth MKM
Ladenburg Thalmann Maintains ChromaDex(CDXC.US) With Buy Rating, Raises Target Price to $8.1
Analysts Offer Insights on Healthcare Companies: Chromadex (CDXC) and Sagimet Biosciences, Inc. Class A (SGMT)
Ladenburg Thalmann Maintains ChromaDex(CDXC.US) With Buy Rating, Raises Target Price to $6.8
Roth MKM Maintains ChromaDex(CDXC.US) With Buy Rating, Maintains Target Price $8
Roth MKM Maintains ChromaDex(CDXC.US) With Buy Rating, Raises Target Price to $8
ChromaDex Analyst Ratings